ID | 1079 |
Name of the vaccine | DT Generic |
Microbe | Bacteria |
Disease name | Tetanus (Lock Jaw) |
Name of bacteria | Clostridium tetani |
Type of vaccine | Inactivated |
Nucleic acid content | DNA |
Age | 6 weeks to 6 years |
Description of the vaccine | Diphtheria and tetanus toxoids adsorbed (DT vaccine). |
Name of the manufacturer | Sanofi Pasteur Limited |
Name of the manufacturing country | Canada |
Year of manufacture | 1997 |
Clinical Phase status | Approved |
Bacterial strain | An obligate anaerobic bacillus, which is gram positive. |
Efficacy | NA |
Vaccine formulation | Suspension for injection |
Dosage | Five doses at 2, 4, 6, 15-18 months and between 4 and 6 years. |
Mechanism of action | Serum diphtheria antitoxin level of 0.01 IU/mL is minimum protection level. |
Route of administration | Intramuscular |
Indications | Active immunization against diphtheria and tetanus. |
Export | Distributed by Sanofi Pasteur Inc, USA |
Approval | US FDA |
Adjuvant | NA |
Repurposing | For diphtheria also. |
Side effects of vaccine | Crying, fever, and loss of appetite. |
Post vaccination | NA |
Dose type | Combination doses |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NA |
Reference | https://www.fda.gov/media/119411/download |
Other name | NA |
Additional Links | NA
|